170 related articles for article (PubMed ID: 21109771)
1. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
[TBL] [Abstract][Full Text] [Related]
3. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F; Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16811-6. PubMed ID: 19805378
[TBL] [Abstract][Full Text] [Related]
4. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
5. An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes.
Cocco L; Finelli C; Mongiorgi S; Clissa C; Russo D; Bosi C; Quaranta M; Malagola M; Parisi S; Stanzani M; Ramazzotti G; Mariani GA; Billi AM; Manzoli L; Follo MY
J Leukoc Biol; 2015 Nov; 98(5):769-80. PubMed ID: 25977289
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
[TBL] [Abstract][Full Text] [Related]
7. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
[TBL] [Abstract][Full Text] [Related]
8. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
9. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Voso MT; Santini V; Finelli C; Musto P; Pogliani E; Angelucci E; Fioritoni G; Alimena G; Maurillo L; Cortelezzi A; Buccisano F; Gobbi M; Borin L; Di Tucci A; Zini G; Petti MC; Martinelli G; Fabiani E; Fazi P; Vignetti M; Piciocchi A; Liso V; Amadori S; Leone G
Clin Cancer Res; 2009 Aug; 15(15):5002-7. PubMed ID: 19638460
[TBL] [Abstract][Full Text] [Related]
11. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Wang AH; Wei L; Chen L; Zhao SQ; Wu WL; Shen ZX; Li JM
Ann Hematol; 2011 Aug; 90(8):917-31. PubMed ID: 21340723
[TBL] [Abstract][Full Text] [Related]
13. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
[TBL] [Abstract][Full Text] [Related]
15. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Filì C; Malagola M; Follo MY; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C; Candoni A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D
Clin Cancer Res; 2013 Jun; 19(12):3297-308. PubMed ID: 23596104
[TBL] [Abstract][Full Text] [Related]
16. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
19. Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor.
Damm F; Lange K; Heuser M; Oberacker T; Morgan M; Wagner K; Krauter J; Schlegelberger B; Ganser A; Göhring G
J Clin Oncol; 2010 Aug; 28(22):e384-7; author reply e388-9. PubMed ID: 20516454
[No Abstract] [Full Text] [Related]
20. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
